deCODE genetics (Nasdaq: DCGN) will webcast
its presentation at the BIO CEO and Investor Conference on Tuesday
February 14. The presentation will be delivered at 3pm EST/8pm GMT, in
the Astor Salon at the Waldorf Astoria hotel in New York. deCODE CEO
Dr. Kari Stefansson will provide an overview of the company's drug
development programs and business. Dr. Stefansson is also scheduled to
participate in a panel discussion at the conference entitled "Genomics
is back," to take place at 3:30pm EST/8:30pm GMT on Wednesday February
15. The conference organizers plan to make available a webcast of this
panel discussion a few hours after the event.
The company presentation webcast can be accessed through the Investors page on deCODE's website, http://www.decode.com
and will be archived for at least one week. A link to the webcast
of the panel discussion will also be posted on the same site. Those
interested in listening should log on a few minutes in advance, in
order to download any software or complete any sign-in that may be
required.
About deCODE
deCODE genetics (Nasdaq: DCGN) is a
biopharmaceutical company applying its discoveries in human genetics to
the development of drugs for common diseases. deCODE is a global leader
in gene discovery -- our population approach and resources have enabled
us to isolate key genes contributing to major public health challenges
from cardiovascular disease to cancer, genes that are providing us with
drug targets rooted in the basic biology of disease. deCODE is also
leveraging its expertise in human genetics and integrated drug
discovery and development capabilities to offer innovative products and
services in DNA-based diagnostics, bioinformatics, genotyping,
structural biology, drug discovery and clinical development. deCODE is
delivering on the promise of the new genetics.(SM) Visit us on the web
at http://www.decode.com.
